Business
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company
About this update from Aptevo Therapeutics Inc.
[{"type":"text","content":"SEATTLE, WA / ACCESSWIRE / January 11, 2021 / Aptevo Therapeutics Inc. (\"Aptevo\" or the \"Company\") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today provided an update on its ongoing APVO436 phase 1 clinical trial.The Company noted that patient dosing in cohorts 1 through 8 has been completed and enrollment in cohort 9 has commenced. A total of 36 patients have been enrolled and treated with APVO436 to date. No evidence of dose-limiting toxicities (DLTs) was observed in cohorts 5-8.\"2020 was a very busy and exciting year at Aptevo, with progress on many fronts. Notably, two patients in cohort 6 of our APVO436 Phase 1a clinical trial achieved complete remission. This development greatly encouraged our research partners and our inhouse teams, who have poured their passion and energy into this trial,\" said Mr. Marvin White, President and CEO of Aptevo Therapeutics.\"In 2021, we look forward to advancing our APVO436 clinical trial and improving patient outcomes, while recognizing that each patient is unique. Our first patient in cohort 6 who had complete remission continues therapy, while the second patient in cohort 6 who also had complete remission progressed and discontinued therapy. Importantly, we are now in a critical phase of the study, within the therapeutic range,\"\"We believe that the work we are doing is meaningful and important, and we will continue to focus on developing candidates that target cancers, ultimately increasing a patients' chance of survival. We have multiple candidates moving towards clinical development, and our ADAPTIR and ADAPTIR-FLEX technology platforms are uniquely positioned to develop and advance our studies,\" concluded Mr. White.About APVO436APVO436 is an optimized bispecific antibody candidate designed to simultaneously target CD123 and CD3 and redirect T-cell cytotoxicity to the tumor. It is currently being evaluated in a Phase 1/1b open-label, dose-escalation study evaluating the safety and pharmacokinetic profile. APVO436 was built on Aptevo's proprietary ADAPTIR protein therapeutic platform. Focused on generating novel, targeted bispecific antibody-based immunotherapies for cancer the ADAPTIR platform offers key advantages over other bispecific ...